News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Progenics Pharmaceuticals, Inc. (PGNX) And Centre For Probe Development And Commercialization Announce Agreement To Manufacture Targeted Radiotherapeutic Candidate For Ultra-Orphan Indications


4/2/2014 9:16:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TARRYTOWN, N.Y. and HAMILTON, Ontario, April 1, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), and Centre for Probe Development and Commercialization (CPDC) today announced that Azedra™, a novel targeted radiotherapy candidate resuming phase 2 registrational testing in patients suffering from pheochromocytoma and paraganglioma, will be manufactured by CPDC for the developer of the compound, Progenics Pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES